Monoclonal Or Polyclonal Antibody Or Immunoglobulin Or Fragment Thereof That Is Conjugated Or Adsorbed (e.g., Adsorbed To A Solid Support, Etc.) Patents (Class 530/391.1)
-
Publication number: 20130245236Abstract: The present invention relates to an antibody binding to murine XCR1. Furthermore, the present invention relates to a nucleic acid molecule encoding for said antibody, a vector comprising said nucleic acid molecule and a host cell comprising said vector. The present invention further embraces a method for producing the antibody. Moreover, the present invention claims the use of the antibody and a kit for detecting murine XCR1+ cells and/or separating murine XCR1+ cells from other cells.Type: ApplicationFiled: March 13, 2013Publication date: September 19, 2013Inventor: Richard KROCZEK
-
Publication number: 20130236966Abstract: Provided herein are conjugates including a targeting vehicle coupled to an agent. The targeting vehicle includes a tachykinin receptor ligand and a reactive moiety. Conjugates including a tachykinin receptor ligand attached to an antibody or fragment thereof that is specific for an intracellular target are also provided. Also provided are methods of delivering agents to cells expressing tachykinin receptors, methods of delivering antibodies or fragments thereof to an intracellular extra-endosomal target, and methods of arresting cell growth or introducing cell death of a cancer cell.Type: ApplicationFiled: December 14, 2012Publication date: September 12, 2013Applicant: THE UNIVERSITY OF CHICAGOInventors: Anthony Kossiakoff, Shahir Rizk
-
Publication number: 20130236398Abstract: Antibodies and antibody fragments that selectively bind to nanoparticles are provided herein.Type: ApplicationFiled: March 12, 2012Publication date: September 12, 2013Applicant: Empire Technology Development LLCInventor: Michael Keoni Manion
-
Publication number: 20130236479Abstract: The present invention relates to a novel method for the delivery of agents to tumour cells. In particular it relates to a method for the specific delivery of agents to the interior of tumour cells. Uses of the method are also described.Type: ApplicationFiled: April 19, 2013Publication date: September 12, 2013Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Miles William Carroll, Abigail Lamikanra, Alan John Kingsman
-
Patent number: 8530627Abstract: The present invention relates to antibodies or fragments thereof that specifically bind Fc?RIIB, particularly human Fc?RIIB, with greater affinity than said antibodies or fragments thereof bind Fc?RIIA, particularly human Fc?RIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.Type: GrantFiled: July 3, 2008Date of Patent: September 10, 2013Assignee: MacroGenics, Inc.Inventors: Scott Koenig, Maria Concetta Veri
-
Publication number: 20130230525Abstract: Provided herein in certain embodiments are polypeptide complexes capable of binding to an antigen. Pharmaceutical compositions, method of using the polypeptide complexes are also provided.Type: ApplicationFiled: November 9, 2011Publication date: September 5, 2013Applicant: ALTIMAB THERAPEUTICS, INC.Inventors: Zijuan Li, Chun Wu, Jun Bao, Bo Chen
-
Publication number: 20130230537Abstract: The present invention is directed to Clostridium difficile toxin-specific antibodies, compositions, and uses thereof. The anti-toxin antibodies may be specific for either TcdA or TcdB. The invention also includes methods of treating a Clostridium difficile infection, methods of capturing Clostridium difficile toxins, and methods of detecting Clostridium difficile toxins.Type: ApplicationFiled: October 25, 2011Publication date: September 5, 2013Inventors: Greg Hussack, Mehdi Nath Arbabi-Ghahroudi, Roger Mackenzie, Jamshid Tanha
-
Publication number: 20130230898Abstract: The invention relates to a method for the preparation of a hydroxyalkyl starch derivative which comprises reacting hydroxyalkyl starch (HAS) via the optionally oxidised reducing end of the HAS with the amino group M of a crosslinking compound which, apart from the amino group, comprises a specifically protected carbonyl group, namely an acetal group or a ketal group.Type: ApplicationFiled: February 19, 2013Publication date: September 5, 2013Applicant: Fresenius Kabi Deutschland GmbHInventors: Frank Hacket, Thomas Hey, Franziska Hauschild, Helmut Knoller, Martin Schimmel, Klaus Sommermeyer
-
Patent number: 8524460Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.Type: GrantFiled: April 8, 2011Date of Patent: September 3, 2013Assignee: The Regents of the UniversityInventors: Robert E. Reiter, Owen N. Witte
-
Publication number: 20130224220Abstract: The present invention relates to an antibody, particularly a monoclonal antibody, which binds to the ErbB3 receptor, compositions comprising such an antibody as well as methods using such an antibody.Type: ApplicationFiled: September 12, 2011Publication date: August 29, 2013Applicant: MEDIAPHARMA S.R.L.Inventors: Raffaella Muraro, Stefano Iacobelli, Nicola Tinari, Sara Traini, Gianluca Sala
-
Publication number: 20130224227Abstract: This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.Type: ApplicationFiled: April 21, 2011Publication date: August 29, 2013Inventors: Patrick Henry Beusker, Rudy Gerardus Elisabeth Coumans, Ronald Christiaan Elgersma, Wiro Michael Petrus Bernardus Menge, Johannes Albertus Frederikus Joosten, Henri Johannes Spijker, Franciscus Marinus Hendrikus de Groot
-
Publication number: 20130224759Abstract: Methods, devices, kits and compositions for detecting the presence or absence of roundworm in a mammalian sample are disclosed herein. The methods, devices, kits and compositions of the present invention may be used to confirm the presence or absence of roundworm in a fecal sample from a mammal that may also be infected with one or more of hookworm, whipworm, and heartworm. Confirmation of the presence or absence of roundworm in the mammal may be made, for example, for the purpose of selecting an optimal course of treating the mammal and/or for the purpose of determining whether the mammal has been rid of the infection after treatment has been initiated.Type: ApplicationFiled: August 14, 2012Publication date: August 29, 2013Applicants: DIVERGENCE, INC., IDEXX LABORATORIES, INC.Inventors: David Allen Elsemore, Laurie A. Flynn, Michael Crawford, Jinming Geng
-
Patent number: 8518653Abstract: A binding partner, especially an antibody fragment that specifically recognizes an antigen-antibody immune complex between anti-THC and THC (tetrahydrocannabinol), is disclosed. The binding partner facilitates a non-competitive homogenous immunoassay for detection of cannabis use. A test kit comprising the binding partner is also described. Preferably the immunoassay is applied for roadside testing of saliva from suspected drivers.Type: GrantFiled: June 5, 2009Date of Patent: August 27, 2013Assignee: Teknologian Tutkimuskeskus VTTInventors: Kristiina Takkinen, Hans Söderlund, Timo Pulli
-
Patent number: 8518403Abstract: A composite polypeptide, said composite polypeptide comprising a desired polypeptide and an expression enhancing domain (“EED”), said EED comprising first and second cysteine amino acid residues Cys1 and Cys2, respectively, Cys1 being located closer to the N-terminus of the composite polypeptide molecule than Cys2, wherein Cys1 and Cys2 are separated by a polypeptide linker, said linker—being free of cysteine and proline;—defining a length sufficient to allow Cys1 and Cys2 to engage in an intramolecular disulfide bond with one another; and—having a flexible polypeptide conformation essentially free of secondary polypeptide structure in aqueous solution, wherein at least one of Cys1 and Cys2 is derivatized with a derivatization moiety.Type: GrantFiled: July 15, 2005Date of Patent: August 27, 2013Assignee: Amgen Research (Munich) GmbHInventors: Patrick Hoffmann, Silke Mittelstrass, Jens Hennecke, Tobias Raum
-
Publication number: 20130216546Abstract: Methods of treating individuals with a glucose metabolism disorder, and compositions suitable for use in the methods, are provided.Type: ApplicationFiled: December 14, 2012Publication date: August 22, 2013Applicant: NGM BIOPHARMACEUTICALS, INC.Inventor: NGM Biopharmaceuticals, Inc.
-
Publication number: 20130217044Abstract: Disclosed are a protein and a gene each of which is a factor involved in latent infection with a herpesvirus. An antibody against the factor was detected in approximately 50% of patients suffering from mental disorders, whereas the antibody was hardly detected in healthy persons. Further, a mouse having SITH-1 introduced therein developed a mental disorder such as a manic-depressive illness or depression-like disorder. Based on these findings, it is possible to provide a method for objectively determining a mental disorder and an animal model of a mental disorder.Type: ApplicationFiled: January 2, 2013Publication date: August 22, 2013Applicants: JAPAN TOBACCO INC., VIRUS IKAGAKU KENKYUSHO INC.Inventors: Virus Ikagaku Kenkyusho Inc., Japan Tobacco Inc.
-
Publication number: 20130217612Abstract: The present invention includes the complete genome sequence for the methanogen, Methanobrevibacter ruminantium, including polynucleotides which encode M. ruminantium polypeptides or peptides, as well as polynucleotides from non-coding regions. Also included are the encoded M. ruminantium polypeptides and peptides, and antibodies directed to these peptides or polypeptides, in addition to expression vectors and host cells for producing these peptides, polypeptides, polynucleotides, and antibodies. The invention further includes methods and compositions for detecting, targeting, and inhibiting microbial cells, especially methanogen cells such as M. ruminantium cells, using one or more of the disclosed peptides, polypeptides, polynucleotides, antibodies, expression vectors, and host cells.Type: ApplicationFiled: August 27, 2010Publication date: August 22, 2013Inventors: Eric Heinz Altermann, Graeme Trevor Attwood, Gregory Cook, Debjit Dey, Scott A. Ferguson, Petrus Hendricus Janssen, William John Kelly, Zhanhao Kong, Suzanne Lambie, Sinead Christine Leahy, Dong Li, Duncan McMillan, Sharla McTavish, Diana Pacheco, Robert Starr Ronimus, Carrie Sang, Carl Yeoman
-
Patent number: 8513388Abstract: The present invention relates to novel antibodies that bind specifically to human Notch 3 and their use in the detection and/or diagnosis of Notch 3 related diseases, such as cancer. The present invention also includes nucleic acids encoding these novel antibodies, vectors and cell lines harboring the nucleic acids, and kits comprising the antibodies for use in the detection and diagnosis.Type: GrantFiled: June 30, 2011Date of Patent: August 20, 2013Assignee: Genentech, Inc.Inventors: Kang Li, Sek Chung Fung, Zhengbin Yao
-
Patent number: 8507214Abstract: The present invention provides an ELISA kit for detecting lincomycin comprising a coating antigen and an enzyme labeled reagent, wherein the coating antigen is selected from the group consisting of a lincomycin hapten-carrier protein conjugate, a lincomycin antibody and a lincomycin anti-antibody; when the coating antigen is the lincomycin hapten-carrier protein conjugate, the enzyme labeled reagent is an enzyme-labeled lincomycin anti-antibody; when the coating antigen is the lincomycin antibody, the enzyme labeled reagent is an enzyme-labeled lincomycin hapten-carrier protein conjugate; and when the coating antigen is the lincomycin anti-antibody, the enzyme labeled reagent is an enzyme-labeled lincomycin hapten-carrier protein conjugate; and the lincomycin hapten is obtained through the condensation reaction between lincomycin and succinic anhydride.Type: GrantFiled: September 27, 2008Date of Patent: August 13, 2013Assignee: Beijing Kwinbon Biotechnology Co., Ltd.Inventors: Fangyang He, Yuping Wan, Caiwei Feng, Zhengmiao Zhao, Caimao Feng, Shanliang Wang, Xiaoqin Luo, Xiaobin Ma
-
Publication number: 20130202615Abstract: Provided are monoclonal antibodies and antigen binding fragments thereof that specifically bind vascular endothelial growth factor (VEGF). The anti-VEGF monoclonal antibodies block VEGF binding to its receptors (e.g., VEGFR1 and/or VEGFR2) and prevent phosphorylation of VEGFR2 by VEGF. Also provided are methods of using the monoclonal anti-VEGF antibodies for treatment of disease, including cancer.Type: ApplicationFiled: June 14, 2011Publication date: August 8, 2013Applicant: VACCINEX, INC.Inventors: Leslie A. Croy, Mark J. Paris, Ernest S. Smith
-
Publication number: 20130203060Abstract: Nucleic acids encoding a new family of small cysteine rich soluble proteins, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.Type: ApplicationFiled: April 1, 2013Publication date: August 8, 2013Applicant: Merck Sharp & Dohme Corp.Inventor: Merck Sharp & Dohme Corp.
-
Publication number: 20130202597Abstract: The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domains, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.Type: ApplicationFiled: August 12, 2011Publication date: August 8, 2013Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Haren Arulanantham, Thil Dinuk Batuwangala, Elena De Angelis, Carolyn Enever, Haiqun Liu, Oliver Schon
-
Publication number: 20130203111Abstract: The invention features compositions and methods for site-specific modification of proteins by incorporation of an aldehyde tag. Enzymatic modification at a sulfatase motif of the aldehyde tag through action of a formylglycine generating enzyme (FGE) generates a formylglycine (FGly) residue. The aldehyde moiety of FGly residue can be exploited as a chemical handle for site-specific attachment of a moiety of interest to a polypeptide.Type: ApplicationFiled: December 7, 2012Publication date: August 8, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: The Regents of the University of California
-
Patent number: 8501427Abstract: The invention relates to antibodies, including monoclonal and polyclonal, or fragments thereof, which discriminate between the histidine and tyrosine isoforms of Complement Factor H and to their use in diagnostic methods and therapeutic treatments relating to Complement Factor H mediated diseases.Type: GrantFiled: January 23, 2008Date of Patent: August 6, 2013Assignee: University College Cardiff Consultants LimitedInventors: Bryan Paul Morgan, Claire Louise Harris, Svellana Hakobyan
-
Publication number: 20130197199Abstract: It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.Type: ApplicationFiled: September 28, 2011Publication date: August 1, 2013Applicants: NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY, NB HEALTH LABORATORY CO., LTD.Inventors: Kiyoshi Takayama, Tomoko Shimizu, Yuji Urushibata, Yukihiko Sugimoto
-
Publication number: 20130195869Abstract: An object of the present invention is to provide a novel anti-human CCR7 antibody useful as a therapeutic agent for tissue fibrosis or cancer, and a pharmaceutical composition containing the anti-human CCR7 antibody, and the like. An anti-human CCR7 antibody specifically binding to an extracellular domain of human CCR7, having a heavy chain CDR3 containing an amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 27, SEQ ID NO: 37, SEQ ID NO: 47, SEQ ID NO: 57, SEQ ID NO: 67, or SEQ ID NO: 77 is provided. Also provided is an anti-human CCR7 antibody having heavy chain CDRs 1-3 and light chain CDRs 1-3 containing amino acid sequences represented by SEQ ID NOs: 5-10, 15-20, 25-30, 35-40, 45-50, 55-60, 65-70, or 75-80. Preferably, the antibody has an activity of interfering with a CCR7-dependent intracellular signal transduction mechanism caused by CCR7 ligand stimulation.Type: ApplicationFiled: September 27, 2011Publication date: August 1, 2013Applicants: NB Health Laboratory Co., Ltd, Sekisui Chemical Co., Ltd.Inventors: Naoki Nishiguchi, Akiyoshi Hirayama, Masahiro Furutani, Tatsuo Shimizu, Kiyoshi Takayama, Tomoko Shimizu, Kazuya Suzuki
-
Publication number: 20130197195Abstract: There is provided a method for covalent immobilization of at least one molecule comprising at least one amino group, said method comprising the sequential steps of: a) providing a surface comprising —SH groups, b) oxidizing the surface comprising —SH groups using redox reactions in the presence of noble metal ions, and c) contacting the surface with at least one molecule comprising at least one amino group to obtain a covalent binding of the at least one molecule to the surface, wherein said at least one amino group is involved in obtaining said covalent bond. The immobilized molecules are immobilized via stable covalent bonds. The method is more versatile since it can be performed as a one step method. All reaction steps are performed in aqueous solution. All steps can be performed at room temperature. The chemicals used are less expensive and less toxic compared to the prior art.Type: ApplicationFiled: July 27, 2011Publication date: August 1, 2013Applicant: LAB-ON-A-BEAD ABInventors: Sven Oscarsson, Kristofer Eriksson, Leif Nyholm
-
Publication number: 20130189287Abstract: The present application relates to methods for the functionalization of immunoglobulins, in particular with drugs.Type: ApplicationFiled: December 21, 2012Publication date: July 25, 2013Applicants: Innate PharmaInventors: Innate Pharma, Paul Scherrer Institut
-
Publication number: 20130190386Abstract: MicroRNA profiles transition from normal breast to ductal carcinoma in situ and transition to invasive ductal carcinoma (IDC) and methods of use thereof are described. Methods of diagnosis and prognosis using microRNA signatures to differentiate invasive from in situ carcinoma are described. Also described is the use of microRNA expression for predicting overall survival and time to metastasis.Type: ApplicationFiled: January 22, 2013Publication date: July 25, 2013Applicant: The Ohio State UniversityInventor: The Ohio State University
-
Patent number: 8492097Abstract: The present invention discloses specific human metapneumovirus monoclonal antibodies. The antibody is at least two-fold less reactive with non-human metapneumoviruses including, but not limited to, respiratory viruses or avian metapneumoviruses. Further, the antibody is at least two-fold more reactive with a human metapneumovirus (i.e., for example, Type A or Type B) than with non-human metapneumoviruses including, but not limited to, respiratory viruses or avian metapneumoviruses. Consequently, these novel antibodies are useful as a clinical diagnostic agent, especially when using fresh nasopharengeal aspirates. The invention also contemplates numerous diagnostic platforms that together with the novel antibodies can support economical, fast, and highly selective detection and identification of clinical inoculum samples.Type: GrantFiled: April 24, 2006Date of Patent: July 23, 2013Assignee: Diagnostic Hybrids, Inc.Inventors: Giuseppe Gerna, Antonella Sarasini, Maria Grazia Revello
-
Patent number: 8491891Abstract: A number of human beta-glucuronidase variants having higher enzymatic activity at physiological pH as compared with wild-type beta-glucuronidase and uses thereof in prodrug therapy. Also disclosed herein is a method for identifying enzyme variants having elevated enzymatic activity using a mammalian surface display system.Type: GrantFiled: November 25, 2009Date of Patent: July 23, 2013Assignee: Academia SinicaInventors: Steve Roffler, Chia-Hung Wu, Wolfgang Schechinger, Kai-Chuan Chen, Zeljko Prijovic
-
Patent number: 8491905Abstract: Disclosed herein is a method of treating dry eye with a KLK-13 antibody.Type: GrantFiled: June 28, 2012Date of Patent: July 23, 2013Assignee: Allergan, Inc.Inventors: Michael E. Stern, Karyn F. Siemasko, Christopher Schaumburg, Jianping Gao
-
Patent number: 8486657Abstract: It is disclosed herein that antibodies specific for preproproteins or preproteins, which are synthesized by certain types of cells or tissues, can be used in immunohistochemistry assays to discriminate between the intracellular component of the protein (including the preproprotein, preprotein and/or proprotein forms of the protein) from the secreted component of the same protein. Accordingly, provided herein is an immunohistochemical method for specific detection of the intracellular form of a protein in a biological sample using an antibody specific for the preproprotein or preprotein form of the protein. In particular examples, the protein is albumin or an immunoglobulin light chain. Also disclosed herein are preproprotein-specific ore preprotein-specific antibodies that can be used to detect specific cell types, tissue lesions or other pathological foci and metastases by IHC. In particular, antibodies that specifically bind human preproalbumin, but do not bind the secreted form of albumin are disclosed.Type: GrantFiled: March 22, 2010Date of Patent: July 16, 2013Inventors: Xiaohong Cai, Thomas Cai
-
Publication number: 20130178606Abstract: Provided is a recombination protein which binds specifically to troponin I derived from human myocardium. The recombinant protein includes a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 63; and a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 65.Type: ApplicationFiled: January 25, 2013Publication date: July 11, 2013Applicant: PANASONIC CORPORATIONInventor: PANASONIC CORPORATION
-
Publication number: 20130178543Abstract: A method of detecting a cancer stem cell or circulating tumor cell that has undergone epithelial-mesenchymal transition, comprising determining the level of caveolin-1 expressed by a sample cell, and comparing the level of caveolin-1 expressed by the sample cell to a control, wherein higher expression of caveolin-1 by the sample cell indicates that the sample cell is a cancer cell, as well as a method of detecting cancer or metastasis in a subject, and related methods and compositions.Type: ApplicationFiled: August 24, 2012Publication date: July 11, 2013Applicants: AJOU UNIVERSITY INDUSTRY COOPERATION FOUNDATION, SAMSUNG ELECTRONICS CO., LTD.Inventors: Yeon-jeong KIM, You-sun KIM, Jeong-gun LEE, Sang-hyun BAEK, Jin-mi OH, Hyo-young JEONG
-
Publication number: 20130178587Abstract: Provided is a method for immobilizing a macromolecule to a solid support material using poly(ethylene glycol), and a device obtained from the method. The macromolecule can be a polypeptide, such as an antibody.Type: ApplicationFiled: May 12, 2011Publication date: July 11, 2013Applicant: Drexel UniversityInventors: David R. Hansberry, Peter M. Clark, Sundar Babu Nadarajan, Constantinos Papathomas
-
Publication number: 20130177500Abstract: Provided herein are novel compositions comprising anti-DEspR antibodies and fragments thereof, including fully human, composite engineered human, humanized, monoclonal, and polyclonal anto-DEspR antibodies and fragments thereof, and methods of their use in a variety of therapeutic applications. The compositions comprising the anti-DEspR antibodies and fragments thereof described herein are useful in diagnostic and imaging methods, such as DEspR-targeted molecular imaging of angiogenesis, and for companion diagnostic and/or in vivo-non invasive imaging and/or assessments.Type: ApplicationFiled: July 22, 2011Publication date: July 11, 2013Applicant: Trustee of Boston UniversityInventors: Nelson Ruiz-Opaz, Victoria L.M. Herrera
-
Patent number: 8481684Abstract: The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the treatment of tumour metastases.Type: GrantFiled: August 9, 2012Date of Patent: July 9, 2013Assignee: Philogen S.p.A.Inventors: Jascha-Nikolai Rybak, Christoph Rosli, Alessandra Villa, Giovanni Neri, Dario Neri
-
Patent number: 8481683Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.Type: GrantFiled: November 30, 2007Date of Patent: July 9, 2013Assignee: Medarex, Inc.Inventors: David John King, Alison Witte, Heidi N. LeBlanc, Richard Theolis, Asna Masood, Mark Yamanaka, Kyra D. Zens, Sarah R. Reed, Tim Sproul, Chetana Rao-Naik, David Passmore, Dawn M. Tanamachi, Kristopher Toy
-
Patent number: 8481042Abstract: The present invention relates to pyrrolo[1,4]benzodiazepine (PBD) dimer conjugates, to the compositions comprising them and to their therapeutic application, in particular as anticancer agents. The invention also relates to the process for the preparation of the conjugates, to their application as anticancer agents and to the dimers themselves.Type: GrantFiled: February 24, 2012Date of Patent: July 9, 2013Assignee: SanofiInventors: Alain Commercon, Laurence Gauzy-Lazo
-
Patent number: 8481041Abstract: The present invention concerns methods and compositions for treatment of HIV infection in a subject, utilizing a DNL complex comprising at least one anti-HIV therapeutic agent, attached to an antibody, antibody fragment or PEG. In a preferred embodiment, the antibody or fragment binds to an antigen selected from gp120, gp41, CD4 and CCR5. In a more preferred embodiment the antibody is P4/D10 or 2G12, although other anti-HIV antibodies are known and may be utilized. In a most preferred embodiment, the anti-HIV therapeutic agent is a fusion inhibitor, such as T20, T61, T651, T1249, T2635, CP32M or T-1444, although other anti-HIV therapeutic agents are known and may be utilized. The DNL complex may be administered alone or may be co-administered with one or more additional anti-HIV therapeutic agents.Type: GrantFiled: November 3, 2011Date of Patent: July 9, 2013Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg
-
Patent number: 8481690Abstract: Method of detecting Symmetrical dimethyl arginine (SDMA) in biological samples. SDMA analogs for generating anti-SDMA antibodies having little or no cross-reactivity with asymmetrical dimethyl arginine, arginine, and monomethylarginine. The analogs have a protected or free thiol (—SH) group or hydroxyl (—OH) group that allow them to be linked to a suitable conjugation target which can be, for example, a protein containing molecule of a label. The anti-SDMA antibodies can be used in diagnostic immunoassay for the diagnosis of SDMA associated disorders and/or diseases.Type: GrantFiled: July 30, 2009Date of Patent: July 9, 2013Assignee: IDEXX Laboratories, Inc.Inventors: Yerramilli V. S. N. Murthy, Mahalakshmi Padmanabhan, Michael Atkinson, Kwok Kam Yeung
-
Patent number: 8481686Abstract: The invention provides novel nucleic acids and polypeptides, referred to herein as stresscopin 1 and stresscopin 2, which preferentially activate the CRH-R2 receptor over the R1 receptor. Stresscopins, analogs and mimetics, and related CRH-R2 agonists suppress food intake and heat-induced edema; but do not induce substantial release of ACTH. Stresscopin also finds use in the recovery phase of stress responses, as an anti-inflammatory agent, as a hypotensive agent, as a cardioprotective agent, and in the treatment of psychiatric and anxiolytic disorders. Stresscopin nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways.Type: GrantFiled: October 1, 2010Date of Patent: July 9, 2013Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Sheau Yu Hsu, Aaron J. W. Hsueh
-
Publication number: 20130171652Abstract: The present invention relates to the use of a conjugate of a non-analyte-specific binding protein coupled to a nucleic acid as a blocking reagent in a probe-based detection assay, which uses a probe comprising a proteinaceous analyte-binding partner coupled to a nucleic acid domain to detect an analyte in a sample.Type: ApplicationFiled: July 13, 2011Publication date: July 4, 2013Inventors: Simon Fredriksson, Bonnie Tran
-
Publication number: 20130171153Abstract: The present disclosure provides an isolated protein comprising at least one antibody variable region that is capable of binding to peptidase inhibitor 16 (PI16), wherein the protein is also capable of competitively inhibiting binding of an antibody produced by a hybridoma designated CRCBT-02-001 deposited with the ATCC under Accession Number PTA-10685 to PI16. The present invention also provides use of the protein, e.g., in diagnosis, therapy or to isolate cells, preferably Treg cells.Type: ApplicationFiled: April 18, 2011Publication date: July 4, 2013Applicant: TransBio Ltd.Inventors: Simon Barry, Doreen Krumbiegel, Nicola Ga-Ling Eastaff-Leung, Ian Cameron Nicholson, Heddy Zola
-
Patent number: 8476027Abstract: A binding partner, especially an antibody fragment that specifically recognizes an antigen-antibody immune complex between anti-THC and THC (tetrahydrocannabinol), is disclosed. The binding partner facilitates a non-competitive homogenous immunoassay for detection of cannabis use. A test kit comprising the binding partner is also described. Preferably the immunoassay is applied for roadside testing of saliva from suspected drivers.Type: GrantFiled: June 5, 2009Date of Patent: July 2, 2013Assignee: Teknologian Tutkimuskeskus VTTInventors: Kristiina Takkinen, Hans Söderlund, Timo Pulli
-
Patent number: 8476411Abstract: Non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides, are disclosed. The non-natural amino acids, by themselves or as a part of a polypeptide, can include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Methods for making, modifying, and purifying the non-natural amino acid polypeptides are also disclosed. Further, methods for using such non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, including therapeutic, diagnostic, and other biotechnology uses, are disclosed.Type: GrantFiled: July 7, 2011Date of Patent: July 2, 2013Assignee: Ambrx, Inc.Inventors: Zhenwei Miao, Junjie Liu, Thea Norman, Russell Driver
-
Publication number: 20130156697Abstract: The invention in suitable embodiments is directed to an isolated protein comprising one or more amino acid sequences, each amino acid sequence capable of being functionalized and/or attached in whole and/or in part to one or more or a plurality of elements of one or more types including to cargo elements, forming a composition of elements suitable for use as an in vivo and/or in vitro medicament to treat one or more biological species.Type: ApplicationFiled: December 21, 2012Publication date: June 20, 2013Inventors: FRANCO VITALIANO, GORDANA DRAGAN VITALIANO
-
Publication number: 20130157961Abstract: The invention relates to conjugates that bind to Her2/neu, methods of using conjugates that bind to Her2/neu and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express Her2/neu.Type: ApplicationFiled: April 28, 2011Publication date: June 20, 2013Applicant: ESPERANCE PHARMACEUTICALS, INC.Inventors: Hector Alila, Carola Leuschner, Martha Juban, Ann Coulter
-
Publication number: 20130158237Abstract: Provided is a recombination protein which binds specifically to troponin I derived from human myocardium. The recombinant protein includes a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 63; and a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 65.Type: ApplicationFiled: November 19, 2012Publication date: June 20, 2013Applicant: PANASONIC CORPORATIONInventor: PANASONIC CORPORATION